The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover

Arthritis and Rheumatism

Volumn 48, Issue 5, 2003, Pages 1177-1189

  Wong, Peter K K ^a   Campbell, Ian K ^a   Egan, Paul J ^a   Ernst, Matthias ^b   Wicks, Ian P ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTROPHIN 1; CILIARY NEUROTROPHIC FACTOR; CYTOKINE; GLYCOPROTEIN GP 130; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTIBODY; JANUS KINASE; LEUKEMIA INHIBITORY FACTOR; MONOCLONAL ANTIBODY; ONCOSTATIN M; PROTEIN; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; RECEPTOR SUBUNIT; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; B LYMPHOCYTE ACTIVATION; BONE TURNOVER; DNA POLYMORPHISM; GENETIC STRAIN; INFLAMMATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; BONE REMODELING; CYTOKINE RECEPTOR GP130; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-6; MEMBRANE GLYCOPROTEINS; MICE; RATS; SIGNAL TRANSDUCTION;

EID: 0038667615     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10943     Document Type: Review

References (153)

1. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. Ann Intern Med 1999;130:478-86.
2. Bresnihan B, Alvaro-Gracia J, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
3. Weinblatt ME, Kremer JM, Bankhurst AD. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
4. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood 1995;86:1243-54.
5. Yasukawa K, Hirano T, Watanabe T, Muratani K, Matsuda T, Nakai S, et al. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J 1987;6: 2939-45.
6. Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997;40:1096-105.
7. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe T, Matsuda T, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B-lymphocytes to produce immunoglobulin. Nature 1986;324:73-6.
8. Aarden L, de Groot E, Schaap O, Landsdorp P. Production of hybridoma growth factor by human monocytes. Eur J Immunol 1987;17:1411-6.
9. Van Damme J, Cayphas S, Opdenakker G, Billiau A, van Snick J. Interleukin-1 and poly-(rI):(rC) induce production of a hybridoma growth factor by fibroblasts. Eur J Immunol 1987;171987: 1-17.
10. Van Damme J, Opdenakker G, Simpson R, Rubira M, Cayphas S, Vink A, et al. Identification of the human 26-kD protein, interferon β2 (IFN-β2) as a B-cell hybridoma/plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor. J Exp Med 1987;165:914-9.
11. Houssiau F, Devogelaer J-P, Van Damme J, de Deuxchaisnes C, van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988;31:784-8.
12. Nicola N, Metcalf D, Matsumoto M, Johnson G. Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. J Biol Chem 1983;258:9017-23.
13. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad Sci U S A 1993;90:11924-8.
14. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 1989;74:1241-4.
15. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987;84:7251-5.
16. Lotz M, Jirik F, Kabouridis P, Tsoukas C, Hirano T, Kishimoto T, et al. B cell stimulating factor 2/interleukin-6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med 1988;167: 1253-8.
17. Takai Y, Wong GG, Clark SC, Burakoff SJ, Herrmann SH. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol 1988;140:508-12.
18. Kopf M, Baumann H, Freer G, Feudenberg M, Lamers M, Kishimoto T, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994;368:339-42.
19. Caldenhoven E, Coffer P, Yuan J, van de Stolpe A, Horn F, Kruijer W, et al. Stimulation of the human intercellular adhesion molecule-1 promoter by interleukin-6 and interferon-γ involves binding of distinct factors to a palindromic response element. J Biol Chem 1994;269:21146-54.
20. Romano M, Sironi M, Toniatii C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6: 315-25.
21. Modur V, Li Y, Zimmermann G, Prescott S, McIntyre T. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor α. J Clin Invest 1997;100:2752-6.
22. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin-6 is required for the development of collagen-induced arthritis. J Exp Med 1998;187:461-8.
23. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, et al. Interleukin-6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A 1998;95:8222-6.
24. Sasai M, Saeki Y, Ohshima S, Nishioka K, Mima T, Tanaka T, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 1999; 42:1635-43.
25. Takagi N, Mihara M, Moriya Y, Nishimoto N, Yoshizaki K, Kishimoto T, et al. Blockade of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998;41:2117-21.
26. De Hooge ASK, van de Loo FAJ, Arntz OJ, van den Berg WB. Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis. Am J Pathol 2000;157:2081-91.
27. Aderka D, Le J, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells and in mice. J Immunol 1989;143:3517-23.
28. Aderka D, Maor Y, Novick D, Engelmann H, Kahn Y, Levo Y, et al. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukaemia cells that is induced by tumour necrosis factor -α or -β. Blood 1993;81:2076-84.
29. Ulich T, Guo K, Remick K, Castillo J, Yin S. Endotoxin-induced cytokine gene expression in vivo: IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6. J Immunol 1991;146:2316-23.
30. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark S, Dinarello C. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1 and tumour necrosis factor (TNF) in human mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1980;75:40-7.
31. Xing Z, Gaulide J, Cox H, Baumann H, Jordana M, Lei X-F, et al. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998;101:311-20.
32. Tilg H, Trehu E, Atkins M, Dinarello C, Mier J. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83:113-8.
33. Van de Loo FAJ, Kuiper S, van Enckevort FHJ, Arntz OJ, van den Berg WB. Interleukin-6 reduces cartilage destruction during experimental arthritis. Am J Pathol 1997;151:177-91.
34. Peters M, Odenthal M, Schirmacher P, Blessing M, Fattori E, Ciliberto G, et al. Soluble IL-6R leads to a paracrine modulation of the IL-6-induced acute phase response in double transgenic mice. J Immunol 1997;159:1474-81.
35. Honda M, Yamamoto S, Cheng M, Yasukawa K, Suzuki H, Saito T, et al. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol 1992;148:2175-80.
36. Mullberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 1993;23:473-80.
37. Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 1992;4:96-100.
38. Horiuchi S, Koyanagi Y, Zhou Y, Miyamoto H, Tanaka Y, Waki M, et al. Soluble IL-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol 1994;24:1945-8.
39. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin-6 receptor: mechanisms of production and implications in disease. FASEB 2001;15:43-58.
40. Jones SA, Novick D, Horiuchi S, Yamamoto N, Szalai AJ, Fuller GM. C-reactive protein: a physiological activator of interleukin-6 receptor shedding. J Exp Med 1999;189:599-604.
41. De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble interleukin-6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994;93:2114-9.
42. Gaillard J-P, Batallie R, Brailly H, Zuber C, Yasukawa K, Attal M, et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 1993;23:820-4.
43. Desgeorges A, Gabay CEM, Silacci P, Novick D, Roux-Lombard P, Grau G, et al. Concentrations and origins of soluble interleukin-6 receptor-α in serum and synovial fluid. J Rheum 1997;24: 1510-6.
44. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992;149:2021-7.
45. Peters M, Schirmacher P, Goldschmitt J, Odenthal M, Peschel C, Fattori E, et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin(IL)-6-sIL-6R double transgenic mice. J Exp Med 1997;185:755-66.
46. Hurst S, Wilkinson T, McLoughlin R, Jones S, Horiuchi S, Yamamoto N, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001;14:705-14.
47. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interledkin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Min Res 1996;11:88-95.
48. Wood N, Symons J, Dickens E, Duff G. In situ hybridization of IL-6 in rheumatoid arthritis. Clin Exp Immunol 1992;87:183-9.
49. Guerne P-A, Zuraw B, Vaughan J, Carson D, Lotz M. Synovium as a source of interleukin-6 in vitro. J Clin Invest 1989;83:585-92.
50. Guerne P-A, Carson D, Lotz M. IL-6 production by human articular chondrocytes. J Immunol 1990;144:499-505.
51. Ito A, Itoh Y, Sasaguri Y, Morimatsu M, Mori Y. Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum 1992;35: 1197-201.
52. Brinckerhoff C. Joint destruction in arthritis: metalloproteases in the spotlight. Arthritis Rheum 1991;34:1073-5.
53. Martel-Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier J, Pelletier J. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994;70:807-15.
54. Firestein G. Mechanisms of tissue destruction and cellular activation in rheumatoid arthritis. Curr Opin Rheum 1992;4:348-54.
55. Wong PK, Cuello C, Bertouch JV, Roberts-Thomson PJ, Ahern MJ, Smith MD, et al. The effects of pulse methylprednisolone on matrix metalloproteinase and tissue inhibitor of metalloproteinase-1 expression in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:1067-73.
56. Muraguchi A, Kishimoto T, Miki Y, Kuritani T, Kaieda T, Yoshizaki K, et al. T cell-replacing factor (TRF)-induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J Immunol 1981;127:412-6.
57. Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu H, et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A 1985;82:5490-4.
58. Zilberstein A, Ruggieri R, Korn J, Revel M. Structure and expression of cDNA and genes for human interferon-beta-2, a distinct species inducible by growth-stimulatory cytokines. EMBO J 1986;5:2529-37.
59. Drossaers-Bakker K, Zwinderman A, Vlieland T, van Zeben D, Vos K, Breedveld F, et al. Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum 2002;46:383-90.
60. Takemura S, Klimiuk P, Braun A, Goronzy J, Weyand C. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-8.
61. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum 2002;46:2029-33.
62. Ray A, Tatter S, May L, Sehgal P. Activation of the human "β2-interferon/hepatocyte-stimulating factor/interleukin 6" promoter by cytokines, viruses and second messenger agonists. Proc Natl Acad Sci U S A 1988;85:6701-5.
63. Dendorfer U, Oettgen P, Libermann TA. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol 1994;14:4443-54.
64. Shimizu H, Mitomo K, Watanabe T, Okamoto S, Yamamoto K-I. Involvement of a NF-κB-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol Cell Biol 1990;10:561-8.
65. Zhang Y, Lin J-X, Vilcek J. Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a κB-like sequence. Mol Cell Biol 1990;10:3818-23.
66. Fishman D, Faulds G, Jeffrey R, Mohamed-Ali V, Yudkin J, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
67. Pascual M, Nieto A, Mataran L, Balsa A, Pascual-Salcedo D, Martin J. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immunity 2000;1:338-40.
68. Jeffrey R, Luong L, Ogilvie E, Xia C, Humphries S, Woo P. The -174 single nucleotide polymorphism (SNP) of the interleukin-6 gene associated with systemic arthritis is functionally significant in the context of common haplotypes, alters transcription factor binding and repression by glucocorticoids [abstract]. Arthritis Rheum 2002;46 Suppl 9:S578.
69. Crilly A, Bartlett J, White A, Stirling D, Capell H, Madhok R. Investigation of novel polymorphisms within the 3′ region of the IL-6 gene in patients with rheumatoid arthritis using Genescan analysis. Cytokine 2001;13:109-12.
70. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993;20:259-62.
71. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of RA by blocking IL-6 signal transduction with humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 1998;20: 247-59.
72. Choy EHS, Isenberg DA, Garrod T, Farrow S, Ioannou Y, Bird H, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rhematoid arthritis. Arthritis Rheum 2002;46:3143-50.
73. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994;13:1189-6.
74. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, et al. Increased osteoclast development after estrogen loss: mediation by IL-6. Science 1992;257:88-91.
75. Pascifici R, Brown C, Puschek E, Friedrich E, Slatopolsky E, Maggio E, et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A 1991;88:5134-8.
76. Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, et al. 17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the anti-osteoporotic effect of estrogens. J Clin Invest 1992;89:883-91.
77. Verbruggen A, De Clerck LS, Bridts CH, van Offel JF, Stevens WJ. Flow cytometric determination of interleukin-1β, interleukin-6 and tumour necrosis factor-α in monocytes of rheumatoid arthritis patients: relation with parameters of osteoporosis. Cytokine 1999;11:869-74.
78. Ferrari SL, Garnero P, Emond S, Montgomery H, Humphries SE, Greenspan SL. A functional polymorphic variant in the interleukin-6 gene promoter associated with low bone resorption in postmenopausal women. Arthritis Rheum 2001;44:196-201.
79. Girasole G, Giuliani N, Modena AB, Passeri M, Pedrazzoni M. Oestrogens prevent the increase of human serum soluble interleukin-6 receptor induced by ovariectomy in vivo and decrease its release in human osteoblastic cells in vitro. Clin Endocrinol 1999;51:801-7.
80. Abrahamsen B, Bonnevie-Nielsen V, Ebbesen E, Gram J, Beck-Nielsen H. Cytokines and bone loss in a 5-year longitudinal study: hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist. The Danish Osteoporosis Prevention Study. J Bone Min Res 2000;15:1545-54.
81. Ganapathi M, May L, Schultz D, Brabenac A, Weinstein J, Sehgal P, et al. Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines. Biochem Biophy Res Comm 1988;157:271-7.
82. Gotschlich E. C-reactive protein: a historical perspective. Ann NY Acad Sci 1989;557:9-18.
83. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
84. Molenaar E, Voskuyl A, Familian A, van Mierlo G, Dijkmans B, Hack C. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum 2001;44:997-1002.
85. Gauldie J, Richards C, Northemann W, Fey G, Baumann H. IFNβ2/BSF2/IL-6 is the monocyte-derived HSF that regulates receptor-specific acute phase gene regulation in hepatocytes. Ann NY Acad Sci 1989;557:46-58.
86. Mackiewicz A, Speroff T, Ganapathi M, Kushner I. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 1991;146:3032-7.
87. Yin T, Schendel P, Yang YC. Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin 11. J Exp Med 1992;175:211-6.
88. Trepicchio WL, Bozza M, Pedneault G, Dorner A. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of pro-inflammatory cytokine release and nitric oxide production. J Immunol 1996;157:3627-34.
89. Trepicchio WL, Wang L, Bozza M, Dorner AJ. IL-11 regulates macrophage effector function through the inhibition of nuclear factor-κB. J Immunol 1997;159:5661-70.
90. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995;270: 286-90.
91. Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 1998;41: 1388-97.
92. Maeir R, Ganu V, Lotz M. Interleukin-11, an inducible cytokine in human articular chondrocytes and synoviocytes, stimulates the production of tissue inhibitor of metalloproteinases. J Biol Chem 1993;268:21527-32.
93. Walmsley M, Butler DM, Marinova-Mutafchieva L, Feldmann M. An anti-inflammatory role for IL-11 in established collagen-induced arthritis. Immunology 1998;95:31-7.
94. Moreland LW, Gugliotti R, King KL, Chase W, Weisman M, Greco T, et al. Results of a phase I/II randomised, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res 2001;3:247-52.
95. Romas E, Udagawa N, Zhou H, Tamura T, Saito M, Taga T, et al. The role of gp130-mediated signals in osteoclast development: regulation of interleukin-11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med 1996;183:2581-91.
96. Girasole G, Jilka RL, Passeri G, Manolagas SC. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest 1994;93:1516-24.
97. Metcalf D, Hilton D, Nicola N. Clonal analysis of the actions of the murine leukaemia inhibitory factor on leukaemic and normal murine haemopoietic cells. Leukaemia 1988;2:216-21.
98. Godard A, Gascan H, Naulet J, Peyrant M-A, Jacques Y, Soulillou J-P, et al. Biochemical characteristics and purification of HILDA, a human lymphokine active on eosinophils and bone marrow cells. Blood 1988;71:1618-23.
99. Anegon I, Moreau J-F, Godard A, Jacques Y, Peyrat M, Hallet M, et al. Production of human interleukin for DA cells (HILDA)/ leukemia inhibitory factor (LIF) by activated monocytes. Cell Immunol 1990;130:50-65.
100. Ishimi Y, Abe, Jin CH, Miyaura C, Hong MH, Oshida M, et al. Leukemia inhibitory factor/differentiation-stimulating factor (LIF/D-factor): regulation of its production and possible roles in bone metabolism. J Cell Physiol 1992;152:71-8.
101. Campbell IK, Waring P, Novak U, Hamilton JA. Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor α. Arthritis Rheum 1993;36:790-4.
102. Lotz M, Moats T, Villiger PM. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis. J Clin Invest 1992;90:888-96.
103. Carroll GJ, Bell M. Leukaemia inhibitory factor stimulates proteoglycan resorption in porcine articular cartilage. Rheumatol Int 1993;13:5-8.
104. Giovannini M, Selleri L, Hermanson GG, Evans GA. Localization of the human oncostatin M gene (OSM) to chromosome 22q12, distal to the Ewing's sarcoma breakpoint. Cytogen Cell Genet 1993;62:32-4.
105. Malik N, Kallestad JC, Gunderson NL, Austin SD, Neubauer MG, Ochs V, et al. Molecular cloning, sequence analysis and functional expression of a novel growth regulator, oncostatin M. Mol Cell Biol 1989;9:2847-53.
106. Grenier A, Dehoux M, Boutten A, Arce-Viciosis M, Durand G, Gougerot-Pocidalo M-A, et al. Oncostatin M production and regulation by human polymorphonuclear neutrophils. Blood 1999;93:1413-21.
107. Langdon C, Kerr C, Hassen M, Hara T, Arsenault AL, Richards CD. Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am J Pathol 2000;157:1187-96.
108. Plater-Zyberk C, Buckton J, Thompson S, Spaull J, Zanders E, Papworth J, et al. Amelioration of arthritis in two murine models using antibodies to oncostatin M. Arthritis Rheum 2001;44: 2697-702.
109. Hui W, Bell M, Carroll G. Oncostatin M stimulates resorption and inhibits synthesis of proteoglycan in porcine articular cartilage explants. Cytokine 1996;8:495-500.
110. Rowan AD, Koshy PJ, Shingleton WD, Degnan BA, Heath JK, Vernallis AB, et al. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum 2001;44:1620-32.
111. Rodig S, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998;93:373-83.
112. Stahl N, Farruggella TJ, Boulton TG, Zhong Z, Darnell JE, Yancopoulos GD. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995;267:1349-53.
113. Hibi M, Hirano T. Gab-family adaptor molecules in signal transduction of cytokine and growth factor receptors, and T and B cell antigen receptors. Leuk Lymphoma 2000;37:299-307.
114. Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemicki A, et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 1994;263:89-92.
115. Stahl N, Boulton T, Farruggella T, Ip N, Davis S, Wittuhn B, et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6β receptor components. Science 1994;263:92-5.
116. Zhong Z, Wen Z, Darnell JE. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994;264:95-7.
117. Wegenka UM, Buschmann J, Lutticken C, Heinrich PC, Horn F. Acute phase response factor, a nuclear factor binding to acutephase response elements, is rapidly activated by interleukin-6 at the post-translational level. Mol Cell Biol 1993;13:276-88.
118. Kordula T, Rydel R, Brigham E, Horn F, Heinrich P, Travis J. Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate α1-antichymotrypsin expression in human cortical astrocytes. J Biol Chem 1998;273:4112-8.
119. Zhang D, Sun M, Samols D, Kushner I. Stat3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem 1996;271:9503-9.
120. Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, et al. Targeted disruption of gp130, a common signal transducer for the interleukin-6 family of cytokines, leads to myocardial and hematologic disorders. Proc Natl Acad Sci U S A 1996;93:407-11.
121. Baumann H, Symes A, Comeau M, Morella K, Wang Y, Friend D, et al. Multiple regions within the cytoplasmic domains of the leukemia inhibitory factor receptor and gp130 cooperate in signal transduction in hepatic and neuronal cells. Mol Cell Biol 1994; 14:138-46.
122. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996;15:3651-8.
123. Fukada T, Hibi M, Yamanaka Y, Takahashi-Tezuka M, Fujitani Y, Yamaguchi T, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 1996;5:449-50.
124. Ernst M, Novak U, Nicholson SE, Layton J, Dunn A. The carboxy-terminal domains of gp130-related cytokine receptors are necessary for suppressing embryonic stem cell differentiation: involvement of STAT3. J Biol Chem 1999;274:9729-37.
125. Ohtani T, Ishihara K, Atsumi T, Nishida K, Kaneko Y, Miyata T, et al. Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity 2000;12:95-105.
126. Ernst M, Inglese M, Waring P, Campbell I, Bao S, Clay F, et al. Abolishing STAT signalling from the LIF/IL-6 signal transducer gp130 in mice results in degenerative joint disease, gastrointestinal ulceration and failure of uterine implantation. J Exp Med 2001;194:189-203.
127. Betz UAK, Bloch W, van den Broek MF, Yoshida K, Taga T, Kishimoto T, et al. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hemopoietic, immunological, hepatic and pulmonary defects. J Exp Med 1998;188: 1955-65.
128. Stewart C, Kaspar P, Brunet L, Bhatt H, Gadi I, Kontgen F, et al. Blastocyst implantation depends on maternal expression of leukemia inhibitory factor. Nature 1992;359:76-9.
129. Robb L, Li R, Hartley L, Nandurkar H, Koentgen F, Begley C. Infertility in female mice lacking the receptor for interleukin-11 is due to a defective uterine response to implantation. Nat Med 1998;4:303-8.
130. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002;2:1-7.
131. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387:917-21.
132. Nicholson SE, Wilson TA, Farley A, Starr R, Zhang J-G, Baca M, et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J 1999;18:375-85.
133. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 1999;18:1309-20.
134. Zhang J-G, Fairley A, Nicholson S, Willson T, Zugaro L, Simpson R, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteosomal degradation. Proc Natl Acad Sci U S A 1999;96:2071-6.
135. Endo T, Masuhara M, Yokouchi M, Suzuki H, Sakamoto H, Mitsui K, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997;387:921-4.
136. Naka T, Narazaki M, Hirata M, Matsumoto A, Minamoto S, Aono A, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997;387:924-9.
137. Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, Zhang J-G, et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A 2000;97: 6493-8.
138. Starr R, Metalf D, Elefanty A, Brysha M, Willson T, Nicola N, et al. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci U S A 1998;95:14395-9.
139. Alexander W, Starr R, Fenner J, Scott C, Handman E, Sprigg N, et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999;98:597-608.
140. Metcalf D, Greenhalgh CJ, Viney E, Wilson TA, Starr R, Nicola N, et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 2000;405:1069-73.
141. Marine J, McKay C, Wang D, Topham D, Parganas E, Nakajima H, et al. SOCS3 is essential in the regulation of fetal liver hemopoiesis. Cell 1999;98:617-27.
142. Roberts A, Robb L, Rakar S, Hartley L, Cluse L, Nicola N, et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci U S A 2001;98:9324-9.
143. Egan PJ, Lawlor KE, Alexander WS, Wicks IP. SOCS-1 regulates acute inflammatory arthritis and T cell activation. J Clin Invest 2003;111:915-24.
144. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, et al. Induction of the cytokine signal regulator SOCS3/CIS as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 2001;108:1781-8.
145. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, et al. Specific inhibition of STAT3 signal transduction by PIAS3. Science 1997;278:1803-5.
146. Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A 1998;95:10626-31.
147. Liu B, Gross M, ten Hoeve J, Shuai KA. Transcriptional corepressor of Stat1 with an essential LXXLL signature motif. Proc Natl Acad Sci U S A 2001;98:3203-7.
148. Schimitz J, Weissenbach M, Haan S, Heinrich PC, Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 2000;275:12848-56.
149. Kim H, Hawley T, Hawley R, Baumann H. Protein tyrosine phosphatase 2 (SHP-2) moderates signaling by gp130 but is not required for the induction of acute-phase plasma protein genes in hepatic cells. Mol Cell Biol 1998;18:1525-33.
150. Burdon T, Stracey C, Chambers I, Nichols J, Smith A. Suppression of SHP-2 and ERK signaling promotes self-renewal of mouse embryonic stem cells. Dev Biol 1999;210:30-43.
151. Symes A, Stahl N, Reeves S, Farruggella T, Servidei T, Gearan T, et al. The protein tyrosine phosphatase SHP-2 negatively regulates ciliary neurotrophic factor induction of gene expression. Curr Biol 1997;7:697-700.
152. Boe A, Baiocchi M, Carbonato M, Papoian R, Serlup-Crescenzi O. Interleukin-6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 1999;11:1057-64.
153. Miyakawa Y, Rojnuckarin P, Habib T, Kaushansky K. Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes. J Biol Chem 2001;276: 2494-502.